A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference

Rubinson, Douglas A.; Dillon, Christopher P.; Kwiatkowski, Adam V.; Sievers, Claudia; Yang, Lili; Kopinja, Johnny E.; Rooney, Dina L; Zhang, Mingdi; Ihrig, Melanie; McManus, Michael T.; Gertler, Frank B.; Scott, Martin; Parijs, Luk Van

doi:10.1038/ng1117

Cited by 1,388 publications

(1,104 citation statements)

References 28 publications

Supporting

Mentioning

1,088

Contrasting

Unclassified

Order By: Relevance

“…Plasmids were subsequently purified and sequenced. Lentivirus particles were produced by transient cotransfection of the ferroportin expression vector and packaging vectors (VSVG, pMDLG, and RSV-REV) into 293T cells (52, 53). Viral particles containing control empty vector were prepared similarly.…”

Section: Methodsmentioning

confidence: 99%

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

Pinnix¹,

Miller²,

Wang³

et al. 2010

Science Translational Medicine

245

278

View full text Add to dashboard Cite

Ferroportin and hepcidin are critical proteins for the regulation of systemic iron homeostasis. Ferroportin is the only known mechanism for export of intracellular non–heme-associated iron; its stability is regulated by the hormone hepcidin. Although ferroportin profoundly affects concentrations of intracellular iron in tissues important for systemic iron absorption and trafficking, ferroportin concentrations in breast cancer and their influence on growth and prognosis have not been examined. We demonstrate here that both ferroportin and hepcidin are expressed in cultured human breast epithelial cells and that hepcidin regulates ferroportin in these cells. Further, ferroportin protein is substantially reduced in breast cancer cells compared to nonmalignant breast epithelial cells; ferroportin protein abundance correlates with metabolically available iron. Ferroportin protein is also present in normal human mammary tissue and markedly decreased in breast cancer tissue, with the highest degree of anaplasia associated with lowest ferroportin expression. Transfection of breast cancer cells with ferroportin significantly reduces their growth after orthotopic implantation in the mouse mammary fat pad. Gene expression profiles in breast cancers from >800 women reveal that decreased ferroportin gene expression is associated with a significant reduction in metastasis-free and disease-specific survival that is independent of other breast cancer risk factors. High ferroportin and low hepcidin gene expression identifies an extremely favorable cohort of breast cancer patients who have a 10-year survival of >90%. Ferroportin is a pivotal protein in breast biology and a strong and independent predictor of prognosis in breast cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

Pinnix¹,

Miller²,

Wang³

et al. 2010

Science Translational Medicine

245

278

View full text Add to dashboard Cite

show abstract

“…[79][80][81][82] In general, biosafety is the major concern in the production of retroviral and lentiviral vectors, and currently they are in use in HIV patients only. Adenoviral vectors are widely used both in cells and in vivo; however, their inability to integrate into the genome has proved advantageous in terms of safety but at the cost of inefficient long-term gene silencing.…”

Section: Rnai Deliverymentioning

confidence: 99%

siRNA-based approaches in cancer therapy

2006

View full text Add to dashboard Cite

The availability of the human genome sequence has revolutionized the strategy of employing nucleic acids with sequences complementary to specific target genes to improve drug discovery and target validation. Development of sequence-specific DNA or RNA analogs that can block the activity of selected single-stranded genetic sequences offers the possibility of rational design with high specificity, lacking in many current drug treatments for various diseases including cancer, at relatively inexpensive costs. Antisense technology is one such example that has shown promising results and boasts of yielding the only approved drug to date in the genomics field. However, in vivo delivery issues have yet to be completely overcome for widespread clinical applications. In contrast to antisense oligonucleotides, the mechanism of silencing an endogenous gene by the introduction of a homologous double-stranded RNA (dsRNA), transgene or virus is called post-transcriptional gene silencing (PTGS) or RNA interference. PTGS is a natural mechanism whereby metazoan cells suppress expansion of genes when they come across dsRNA molecules with the same sequence. Short interfering RNA is currently the fastest growing sector of this antigene field for target validation and therapeutic applications. Although, in theory, the development of genomics-based agents to inhibit gene expression is simple and straightforward, the fundamental concern relies upon the capacity of the oligonucleotide to gain access to the target RNA. This paper summarizes the advances in the last decade in the field of PTGS using RNA interference approaches and provides relevant comparisons with other oligonucleotide-based approaches with a specific focus on oncology applications. Cancer Gene Therapy (2006) Genomic-based strategiesThe American Cancer Society estimates that, in 2005, a total of 1 372 910 new cancer cases and 570 280 deaths are expected in the United States. 1 These morbid statistics demonstrate the necessity of newer therapeutic modalities for achieving successful cancer treatment and cure. Downregulation of genes that contribute to cancer progression has been the goal of targeted genomics-based strategies, with the expectation that such an approach may lead to selective and specific inhibition of tumor growth with minimal untoward side effects on normal cells. Identification of target genes involved in neoplastic transformation and tumor progression has triggered the idea that nucleotide sequences of cancer-relevant genes could lead to the development of tailored anticancer agents that lack many of the toxic side effects of traditional cytotoxic drugs. This has led to a recent acceleration in the development and optimization of genomic-based strategies for cancer therapy. This idea dates back to the 1960s when RNA sequences were shown to serve as endogenous inhibitors of gene expression in procaryotes. The antigene approaches include the following:(1) Ribozymes: 2,3 These were discovered in the 1970s, and the elucidation of the transactivating hammerh...

show abstract

“…Retroviral gene expression and shRNA-mediated knockdown Lentiviral vectors used for expression of EGFP (LL3.7) (Rubinson et al, 2003) and EGFP-tagged GLI2act (LL3.7-GLI2act) are described in Kasper et al (2007).…”

Section: Cell Culturementioning

confidence: 99%

Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes

et al. 2009

View full text Add to dashboard Cite

Sustained Hedgehog (HH) signaling is implicated in basal cell carcinoma of the skin and other types of cancer. Here we show that GLI1 and GLI2, the main transcriptional activators of the HH pathway, directly regulate expression of the activator protein 1 (AP-1) family member JUN, a transcription factor controlling keratinocyte proliferation and skin homeostasis. Activation of the JUN promoter by GLI is dependent on a GLI-binding site and the AP-1 sites known to be involved in self-activation of JUN. Transcription of JUN is greatly enhanced in the presence of GLI and requires activated JUN protein.GLI2act is a more potent activator than GLI1 in these experiments and physical interaction with phosphorylated JUN was only detected for GLI2act. The synergistic effect of GLI and JUN extends to the activation of further GLI target genes as shown by shRNA-mediated knockdown of JUN in human keratinocytes. Some of these cooperatively activated genes are involved in cell-cycle progression, which is consistent with a significant reduction of the proliferative potential of GLI in the absence of JUN. These results suggest a novel connection between HH/GLI pathway activity and JUN, which may contribute to the oncogenic activity of HH/GLI signaling in skin.

show abstract

A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference

Cited by 1,388 publications

References 28 publications

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

siRNA-based approaches in cancer therapy

Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes

Contact Info

Product

Resources

About